Alamar Biosciences reports Q3 2026 revenue of $33.5 million

On November 3, 2026, Alamar Biosciences, Inc. (the "Company") issued a press release announcing its financial results for the quarter ended September 30, 2026.^{1 1}A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.¹

All of the information furnished in this Item 2.02 and Exhibit 99.1 of this Current Report on Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.²

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

After more than five years of exemplary service, on October 30, 2026, Timothy "Tod" White informed the Company that he will retire from his current position as President of the Company, effective as of December 31, 2026.³ Mr. White has agreed to remain as a consultant to the Company from January 1, 2027 through June 30, 2027 to ensure an orderly transition and continuity of operations.⁴

Yuling Luo, Ph.D., Founder, Chief Executive Officer, and Chair of the Company said, "Tod has been an outstanding partner and leader during a pivotal period for Alamar."^{5 5}Dr. Luo continued, "He helped build the foundation that is driving our growth today, managed multiple rounds of fundraising, and leaves the company well-positioned for its next phase.^{5 5}On behalf of our board and the entire team, I thank Tod for his many contributions and wish him the very best in his retirement.⁵"

Exhibit number

Description

99.1

Press Release dated November 3, 2026

Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Alamar Biosciences, Inc.

Date:

November 3, 2026

By:

/s/ Justin McAnear

Justin McAnear

Chief Financial Officer

(Principal Financial Officer and Principal Accounting Officer)

Alamar Biosciences Reports Third Quarter 2026 Financial Results and Raises 2026 Revenue Guidance

FREMONT, Calif. Nov. 03, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in precision proteomics dedicated to enabling the earliest detection of disease, today reported financial results for the quarter ended September 30, 2026.

Recent Highlights

• Generated $33.5 million of total revenue for the third quarter of 2026, an increase of 68% as compared to the corresponding period of 2025⁶

• Selected by UK Biobank to profile 80,000 samples for study targeting earlier detection, prevention and treatment of Parkinson's disease, Alzheimer's disease and other neurodegenerative conditions⁸

• Launched a strategic scientific collaboration with GSK for large-scale 60,000-sample study to advance precision medicine across respiratory, liver, kidney, neurological and autoimmune conditions⁹

• Announced publication of first longitudinal treatment response for Alzheimer's disease using NULISA platform published in Lancet Neurology¹⁰

• Raising full-year 2026 revenue guidance to $121 million to $123 million, representing growth of 64% at the midpoint of the range as compared to 2025⁷

"Our third quarter results reflect continued strong demand for our platform, with revenue up 68% and biopharma customers accounting for the largest portion of our revenue for the firs